Drug Trial Radar · NCT04832139
A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) Device
Last checked: Nov 20, 2026Latest source record: Jul 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
22
Actual
Start
Mar 30, 2021
Primary completion
Nov 22, 2021
Study completion Nov 22, 2021
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Apr 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal in this study is to show that there are not significant differences in biologic activity of the study drug when administered using either the prefilled pen and prefilled syringe.
Conditions
- Healthy Volunteers
Interventions
Marstacimab PFPDrug
300 milligrams (mg) subcutaneous injection marstacimab PFP
Marstacimab PFSDrug
300 mg subcutaneous injection of marstacimab PFS
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the plasma concentraiton time Curve from time zero extrapolated to infinite time (AUCinf)Time frame: Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
- Maximum observed plasma concentration (Cmax)Time frame: Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Brussels Clinical Research Unit
Brussels, Bruxelles-capitale, Région de, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.